3 ms·
Intellia pauses phase 3 CRISPR trials after patient is hospitalized
- randycupertino 1y agoCRISPR-based in vivo gene editing biotech Intellia voluntarily paused their Phase III ATTR PN and ATTR CM trials this morning after adverse liver effects in 1 patient. Road towards the first commercially successful gene therapy continues to be rocky.